12:00 AM
Oct 08, 2012
 |  BC Week In Review  |  Company News  |  Other News

Allergan, Merz neurology news

The U.S. District Court for the Central District of California granted a motion from Merz to modify a permanent injunction and terminate portions that prevented Merz from selling Xeomin incobotulinumtoxinA. In March, the court entered an injunction order preventing Merz from selling Xeomin in facial aesthetics indications or in therapeutic indications to certain physicians for 10 months. As modified, the court will lift the restrictions preventing Merz from selling Xeomin in the therapeutics market...

Read the full 359 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >